List of Excipients in Branded Drug HEALTH MART LOPERAMIDE HYDROCHLORIDE

Generic Drugs Containing HEALTH MART LOPERAMIDE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Strategic Sourcing Services LLC	loperamide hcl	62011-0151	ANHYDROUS CITRIC ACID
Strategic Sourcing Services LLC	loperamide hcl	62011-0151	CARBOXYMETHYLCELLULOSE SODIUM
Strategic Sourcing Services LLC	loperamide hcl	62011-0151	CELLULOSE, MICROCRYSTALLINE
Strategic Sourcing Services LLC	loperamide hcl	62011-0151	D&C YELLOW NO. 10

What are the Most Frequently-Used Excipients in HEALTH MART LOPERAMIDE HYDROCHLORIDE?

# Of NDCs	Excipient
2	ANHYDROUS CITRIC ACID
2	CARBOXYMETHYLCELLULOSE SODIUM
2	CELLULOSE, MICROCRYSTALLINE
2	D&C YELLOW NO. 10

Excipient Strategy and Commercial Opportunities for Health Mart Loperamide Hydrochloride

Last updated: August 22, 2026

Health Mart loperamide hydrochloride is a private-label, immediate-release OTC antidiarrheal product competing primarily on price, retail availability, dosage convenience, and package economics. Its active ingredient is an established generic with no meaningful composition-of-matter exclusivity. Commercial differentiation therefore depends on dosage form, excipient tolerability, packaging, dosing clarity, and channel-specific positioning rather than API exclusivity.

Exact inactive ingredients vary by Health Mart NDC and dosage form. A product-level assessment should treat the current FDA Structured Product Labeling record and package label as controlling. The strategic analysis below applies to the standard 2 mg oral loperamide hydrochloride product marketed under the Health Mart name.

What is Health Mart loperamide hydrochloride?

Health Mart loperamide hydrochloride is an OTC antidiarrheal containing loperamide hydrochloride, typically at a 2 mg strength. Loperamide reduces intestinal motility and increases fluid absorption through peripheral opioid-receptor activity in the gastrointestinal tract. At labeled doses, systemic exposure is limited by intestinal P-glycoprotein transport and first-pass metabolism.[1]

Attribute	Commercial assessment
Active ingredient	Loperamide hydrochloride
Typical strength	2 mg per capsule, tablet, or caplet
Therapeutic category	OTC antidiarrheal
Reference-market competitor	Imodium A-D and store-brand equivalents
Primary route	Oral
Typical release profile	Immediate release
Prescription requirement	No, when marketed under applicable OTC requirements
Biosimilar relevance	None
Core commercial buyer	Retail consumer, pharmacy, travel-health purchaser
Principal differentiation	Price, package size, dosage form, excipient profile, availability

FDA labeling generally limits use to short-term symptomatic treatment of diarrhea. Dosing instructions, maximum daily dose, age restrictions, and warnings concerning fever, bloody stool, abdominal swelling, and prolonged symptoms are central to the product’s regulatory and commercial profile.[2]

What excipients are likely used in Health Mart loperamide hydrochloride?

The likely excipient system is a conventional immediate-release oral solid formulation. Depending on whether the product is a hard gelatin capsule, tablet, or caplet, the formulation may include fillers, disintegrants, lubricants, glidants, coating agents, pigments, and capsule-shell materials.

Likely excipient functions

Excipient category	Typical candidates	Function
Diluent	Microcrystalline cellulose, lactose, starch	Provides tablet or fill mass
Disintegrant	Crospovidone, sodium starch glycolate, croscarmellose sodium	Promotes breakup after administration
Binder	Povidone, pregelatinized starch	Improves granule or tablet cohesion
Lubricant	Magnesium stearate, stearic acid	Reduces tooling friction
Glidant	Colloidal silicon dioxide, talc	Improves powder flow
Film coating	Hypromellose, polyethylene glycol, titanium dioxide	Improves appearance, handling, and swallowability
Capsule shell	Gelatin, water, colorants, titanium dioxide	Provides dosage-form enclosure
Color system	Approved synthetic colorants or iron oxides	Product identification and branding

Loperamide hydrochloride has high potency relative to the total dosage-unit mass. The excipient system therefore determines manufacturability more than dose loading. Blend uniformity, segregation control, lubrication time, and content uniformity are important process variables.

A standard capsule or tablet formulation has a low technical barrier. The principal formulation risks are inconsistent disintegration, poor dissolution, powder-flow problems, and excessive lubricant exposure. Excess magnesium stearate or prolonged lubrication can reduce wetting and slow dissolution. A disintegrant level that is too low can produce delayed release in an otherwise immediate-release product.

How should the excipient strategy be optimized?

The strongest strategy for a Health Mart-type product is a platform formulation that supports reliable dissolution, low manufacturing cost, broad consumer tolerability, and multiple package configurations.

1. Use a robust immediate-release matrix

A microcrystalline-cellulose or starch-based filler system can support direct compression or dry granulation. Crospovidone or croscarmellose sodium can provide rapid tablet breakup. The formulation should be designed around:

• Consistent content uniformity at the 2 mg dose
• Rapid disintegration
• Dissolution performance that remains stable across commercial scale
• Low sensitivity to humidity
• Efficient high-speed tableting or capsule filling
• Minimal sticking and picking during compression

For a capsule product, powder-flow performance and fill-weight control become more important than tablet hardness. For a caplet, coating uniformity and mechanical strength become more important.

2. Reduce consumer-exclusion excipients

Excipients can create avoidable purchasing barriers. A competitive private-label product can be positioned as:

• Lactose-free
• Gluten-free, where supported by supplier and manufacturing controls
• Dye-free
• Low-allergen
• Free of artificial flavors
• Gelatin-free, if converted to a tablet or plant-based capsule

Lactose is inexpensive and widely used, but removing it can simplify positioning for lactose-sensitive consumers. Colorants improve product recognition but can complicate clean-label claims. Gelatin capsules are familiar and inexpensive, although tablets provide greater flexibility for vegetarian and vegan positioning.

3. Control moisture and packaging interaction

Loperamide solid oral products should be evaluated for moisture-driven changes in tablet strength, capsule brittleness, dissolution, and appearance. High-barrier blister packaging can provide better unit-dose protection than a conventional bottle, particularly for travel and first-aid channels.

Packaging choices include:

Format	Advantage	Limitation
HDPE bottle	Lowest unit cost; easy retail packaging	Greater in-use moisture exposure
Alu-Alu blister	Strong barrier; travel-friendly	Higher packaging cost
PVC/PVdC blister	Moderate barrier and cost	Lower barrier than Alu-Alu
Child-resistant bottle	Supports safety compliance	Higher opening friction
Unit-dose pouch or blister	Supports portability and adherence	Less efficient for large-count packs

The commercial optimum is likely a standard bottle for value retail and a blister configuration for travel, convenience, and e-commerce multipacks.

What formulation patents protect loperamide hydrochloride products?

The loperamide active ingredient is long genericized. The principal patent opportunity is not API protection but differentiated delivery or packaging technology. Potential claim areas include:

• Orally disintegrating tablets
• Fast-dissolving films
• Taste-masked pediatric dosage forms
• Liquid suspensions
• Effervescent systems
• Modified-release formulations
• Abuse-deterrent formulations
• Unit-dose packaging and dispensing systems

These opportunities have different commercial value. A fast-dissolving formulation may improve convenience but must justify a price premium in a product that consumers often purchase for occasional use. A pediatric liquid may broaden dosing flexibility but increases stability, preservative, microbial, and measuring-device requirements. Modified release is technically possible but poorly aligned with routine short-term diarrhea treatment and may create safety and labeling complexity.

An abuse-deterrent excipient strategy is also unlikely to be a high-value standalone opportunity. Loperamide misuse at very high doses has been associated with serious cardiac risks, including QT prolongation and arrhythmias.[3] The more practical risk controls are package-size limits, prominent warnings, pharmacy monitoring, and clear dosing instructions rather than a complex reformulation.

What is the FDA regulatory status of Health Mart loperamide hydrochloride?

Loperamide is an established OTC active ingredient regulated within FDA’s antidiarrheal drug framework. FDA’s OTC monograph system establishes conditions under which eligible products can be marketed without an individual product approval, subject to applicable monograph, labeling, manufacturing, and registration requirements.[4]

A private-label sponsor may use one of several regulatory structures:

1. Market a product conforming to the applicable OTC monograph.
2. Market an OTC drug under an approved application held by a contract manufacturer or private-label distributor.
3. Use an approved drug listing and labeling structure supported by the responsible manufacturer.

The regulatory burden rises materially when the sponsor changes dosage form, route, concentration, excipient function, or consumer population. An ordinary 2 mg immediate-release capsule or tablet has a lower regulatory risk than an orally disintegrating, pediatric, liquid, or modified-release product.

What is the Orange Book status of Health Mart loperamide hydrochloride?

Health Mart loperamide hydrochloride is generally not a conventional Orange Book patent-risk product in the manner of a prescription NDA. Standard OTC monograph products do not depend on listed innovator patents for market access, and private-label OTC products are not normally exposed to a conventional Paragraph IV launch sequence.

Issue	Assessment
Composition-of-matter patent	Expired or commercially irrelevant
Orange Book-listed product patents	Not expected for a standard OTC monograph product
Paragraph IV challenge	Generally not applicable to the ordinary private-label product
Formulation patent risk	Possible only for a specific differentiated dosage form
Biosimilar pathway	Not applicable
Exclusivity barrier	No meaningful exclusivity expected for standard loperamide
Generic entry	Already established

The relevant IP review should focus on third-party formulation, delivery, packaging, and manufacturing claims rather than the loperamide molecule itself. FDA’s Orange Book remains the reference source for listed patents and exclusivity associated with approved drug applications.[5]

When does loperamide hydrochloride lose exclusivity?

Loperamide hydrochloride has already lost practical market exclusivity. The product has been sold in generic and private-label forms for decades. Health Mart’s commercial protection comes from trademark, retail distribution, supplier agreements, purchasing scale, and shelf placement.

There is no meaningful branded-generic exclusivity period comparable to the exclusivity attached to a newly approved prescription product. A new formulation could create a separate patent position, but any such protection would attach to the formulation or delivery technology, not to ordinary loperamide hydrochloride.

Which companies are challenging Health Mart loperamide hydrochloride?

Health Mart does not face a conventional innovator patent challenge from generic companies because it is itself a private-label generic or OTC product. Competition comes from:

• Johnson & Johnson consumer-health products associated with Imodium A-D
• Perrigo private-label and store-brand suppliers
• CVS Health and Walgreens store brands
• Walmart and Target private-label products
• Amazon and other e-commerce sellers
• Contract manufacturers supplying regional pharmacy chains

The relevant competitive contest is retail substitution. Consumers can switch among products containing 2 mg loperamide hydrochloride with limited clinical differentiation. Brand strength and package recognition support Imodium, while private labels compete on price and availability.

What commercial opportunities exist for excipient-led differentiation?

Premium convenience dosage forms

An orally disintegrating tablet or film could target travelers, consumers without immediate access to water, and convenience-driven buyers. The commercial case depends on adequate taste masking, rapid wetting, mechanical stability, and a retail price above standard capsules.

Dye-free and low-allergen products

A dye-free, lactose-free tablet could capture consumers who avoid colorants or specific excipients. This is a lower-risk opportunity because it can use familiar immediate-release technology without creating a new pharmacologic profile.

Travel and emergency kits

Single-dose blister packs, compact cartons, and first-aid kit configurations can increase gross margin through packaging and convenience. The product is well suited to travel, office, outdoor, and disaster-preparedness channels.

Multi-symptom or co-pack strategies

Co-packaging with oral rehydration salts, electrolyte products, or travel-health items may create a broader basket opportunity. Combining loperamide with other active ingredients in one dosage form requires careful regulatory and clinical review. Co-packaging separate products is less complex than creating a fixed-dose combination.

Institutional and occupational health supply

Bulk-count bottles and unit-dose formats can target employers, universities, hospitality operators, correctional facilities, and institutional pharmacies. These channels prioritize price, reliable supply, and shelf stability.

How strong is the patent estate for a Health Mart loperamide product?

The patent estate is weak for the standard product and potentially moderate for a genuinely differentiated delivery system.

Patent layer	Strength for standard Health Mart product	Commercial implication
Loperamide composition of matter	Very low	No meaningful exclusion
Standard 2 mg tablet or capsule	Very low	Easy substitution
Conventional excipient blend	Low	Limited enforceability
ODT or fast-dissolving film	Moderate, if novel	Possible premium positioning
Pediatric liquid or taste-masked system	Moderate	Higher development and regulatory cost
Modified release	Uncertain	Technical complexity with limited need
Packaging and dispensing	Low to moderate	Useful for channel differentiation
Manufacturing process	Low unless process-specific	Usually difficult to defend commercially

A patent filing should focus on measurable technical advantages, such as improved dissolution under defined conditions, superior stability, reduced friability, taste masking, or manufacturing robustness. Broad claims covering routine excipient substitutions are vulnerable to obviousness challenges.

What generic launch risks exist?

A new loperamide product faces low legal-entry risk but high commercial substitution risk. The product can reach market quickly if it conforms to the applicable OTC requirements, yet it must compete against numerous established suppliers.

Key launch risks include:

• Retail price compression
• Limited shelf space
• Contract-manufacturing capacity constraints
• Packaging-component shortages
• Inconsistent dissolution after scale-up
• Consumer confusion over maximum dosing
• Adverse-event exposure from misuse
• Low repeat-purchase frequency
• Weak differentiation from existing store brands

The best launch model is usually a low-cost base product supported by one differentiated SKU, such as dye-free tablets or travel blister packs. A broad portfolio of novel dosage forms is less attractive unless the sponsor has a strong retail distribution platform.

What licensing and partnership opportunities exist?

Licensing opportunities are more likely in formulation and packaging than in the loperamide molecule. Relevant counterparties include:

• OTC contract manufacturers with existing loperamide capabilities
• Film and orally disintegrating tablet technology licensors
• Blister and unit-dose packaging suppliers
• Retail pharmacy chains seeking exclusive private-label configurations
• Travel-health and first-aid kit companies
• Consumer-health companies with established regulatory infrastructure

An exclusive retail configuration may have greater practical value than a broad formulation license because the market is driven by distribution and procurement economics. A private-label sponsor should seek rights covering formulation know-how, artwork, packaging configuration, regulatory files, and supply continuity.

Key Takeaways

• Health Mart loperamide hydrochloride is a mature OTC private-label product with no meaningful API exclusivity.
• The standard commercial product is an immediate-release 2 mg oral dosage form.
• Excipients should prioritize rapid disintegration, reliable dissolution, low moisture sensitivity, and low manufacturing cost.
• Dye-free, lactose-free, gelatin-free, and travel-oriented formats offer the clearest differentiation.
• The Orange Book and Paragraph IV frameworks have limited relevance to a standard OTC monograph loperamide product.
• Formulation patents may be available for ODTs, films, pediatric systems, or specialized packaging, but routine excipient changes have weak patent value.
• The strongest commercial opportunities are private-label scale, unit-dose packaging, e-commerce multipacks, travel kits, and institutional supply.
• Product safety strategy should emphasize package size, dosing clarity, and misuse warnings rather than relying on excipient-based abuse deterrence.

FAQs

Is loperamide hydrochloride a patented drug?

No. Loperamide hydrochloride is a mature generic active ingredient. Any protectable value would arise from a novel dosage form, delivery system, manufacturing process, or packaging configuration.

Can a private-label loperamide product use a different excipient blend?

Yes, provided the finished product satisfies applicable FDA requirements and remains within the relevant OTC regulatory framework. The change must preserve product quality, stability, labeling compliance, and performance.

Is a loperamide orally disintegrating tablet commercially attractive?

Potentially. It could support premium pricing and travel-oriented positioning, but taste masking, friability, moisture protection, and consumer willingness to pay are critical development issues.

Are loperamide products subject to biosimilar competition?

No. Loperamide is a small-molecule drug, not a biologic. The relevant competition is from generic, private-label, and branded OTC products.

What is the most defensible loperamide formulation opportunity?

A formulation with documented technical performance, such as fast disintegration, improved stability, effective taste masking, or a differentiated unit-dose package, is more defensible than a conventional tablet using a routine alternative excipient.

References

1. National Center for Biotechnology Information. (n.d.). Loperamide hydrochloride. PubChem Compound Summary. https://pubchem.ncbi.nlm.nih.gov/

2. U.S. Food and Drug Administration. (2023). Loperamide hydrochloride drug facts and labeling information. https://www.fda.gov/

3. U.S. Food and Drug Administration. (2018). FDA warns about serious heart problems with high doses of the antidiarrheal medicine loperamide. https://www.fda.gov/

4. U.S. Food and Drug Administration. (2024). Over-the-counter monograph M007: Antidiarrheal drug products for over-the-counter human use. https://www.accessdata.fda.gov/

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book